CAI Caris Life Sciences (CAI) Q4 FY25 earnings call
Caris Life Sciences concluded its first year as a public company with a record-breaking Q4 FY25, driven by robust molecular profiling revenue growth and significant margin expansion. The company achieved strong profitability, generating positive adjusted EBITDA and free cash flow for the third consecutive quarter, bolstering its balance sheet. Strategic investments are planned for 2026 to expand the commercial sales force and advance its differentiated pipeline, particularly the Caris Detect early cancer detection test, while maintaining financial discipline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CAI operating KPIs by quarter
| KPI | This call Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Covered lives MI Cancer Seek | 225M+The key driver for tissue was obviously the impact from our FDA approval and the subsequent increase in pricing and the benefits we saw through contract, where we have now surpassed over 225 million covered lives from MI Cancer Seek.Source: earnings call transcript | 225M+At this point, we're above $225 million covered lives for MI Cancer Seek, which we expect to continue to increase throughout the course of this year, and the assay represented more than 75% of our tissue volume in Q1.Source: earnings call transcript | ~239.5MWith regard to covered lives that now stands at approximately $239.5 million for MI Cancer Seq and $131.9 million for Care Assure and is a testament to the great work by our market access teams as we continue to see improvements across the payer landscape.Source: earnings call transcript | — |
| Procedures | — | 52.8KIn the first quarter, we completed 52,800 cases, up 15% year-over-year.Source: earnings call transcript | 59.2KWe added roughly 6,400 cases in the quarter, a record for sequential case additions that led us to 59,200 cases.Source: earnings call transcript | +12.1% |
| Procedures Tissue | — | ~43.6KFor Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases.Source: earnings call transcript | ~48.3KWith respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially.Source: earnings call transcript | — |
| Procedures Caris Assure | — | ~9,200For Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases.Source: earnings call transcript | 10.7KWith respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.